In an editorial, one expert said the choice of DOAC in VTE is “no longer a toss-up,” with apixaban the clear winner.

Results highlighted in two oral presentations at the American Society of Hematology Annual Meeting In a second oral presentation, results from a sub-group analysis of the primary study were ...

Apixaban halved the risk for bleeding compared with rivaroxaban in the treatment of acute venous thromboembolism in the ...

Significantly lower risk for clinically relevant bleeding seen with apixaban than rivaroxaban during three-month trial period.

In contrast, no added benefit proven in initial treatment of patients with BMI up to 28 kg/m2 and in long-term prevention Institute for Quality and Efficiency in Health Care Apixaban (trade name ...

Apixaban conferred lower bleeding risk during a 3-month period compared with rivaroxaban in patients with acute venous thromboembolism, researchers reported.Despite higher medication adherence to ...

Recent guidelines recommend consideration of the use of oral edoxaban or rivaroxaban for the treatment of venous thromboembolism in patients with cancer. However, the benefit of these oral agents is ...

Patients who have suffered from a first episode of unprovoked venous thromboembolism (VTE) have an eight times higher risk of recurrence if they stop treatment after repeated negative D-dimer tests, ...

The disadvantages of dabigatran include a higher cost compared with warfarin, the need for twice-daily dosing, and a slightly increased risk for gastrointestinal bleeding (6.1% with dabigatran vs 4% ...

Hospital and advocacy group opposition to state public options could foretell trouble for national single-payer efforts; electronic health records (EHRs) present new opportunities for fraud; the FDA ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--The Bristol-Myers Squibb-Pfizer Alliance today announced results from retrospective real-world data analyses reporting outcomes on the safety and ...